ProCE Banner Activity

Targeted Therapy Options in the Second-line Setting for Patients With Advanced HCC

Slideset Download
Download this slideset for expert perspectives on targeted systemic therapy for patients with advanced HCC who have failed an initial systemic regimen.

Released: January 23, 2020

Expiration: January 21, 2021

No longer available for credit.

Share

Faculty

James M. Cleary

James M. Cleary, MD, PhD

Associate Professor of Medicine
Harvard Medical School
Director of Clinical Research
Gastrointestinal Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Eisai

Merck Sharp & Dohme Corp.

Faculty Disclosure

Primary Author

James M. Cleary, MD, PhD

Associate Professor of Medicine
Harvard Medical School
Director of Clinical Research
Gastrointestinal Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts